Carfilozomib versus bortezomib for relapsed or refractory myeloma – Authors' reply. Issue 4 (April 2016) - Dimopoulos, Meletios A; Moreau, Philippe; Palumbo, Antonio; Chng, Wee-Joo; Feng, Shibao